Product/Composition:- | Eliglustat capsule |
---|---|
Strength:- | 84 mg |
Form:- | Capsules |
Reference Brands:- | Cerdelga®(US & EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Eliglustat capsules, used for Gaucher disease type 1, work by inhibiting the enzyme glucosylceramide synthase, reducing harmful enzyme activity. Benefits include effective oral administration, improved disease management, and fewer side effects compared to enzyme replacement therapy, leading to better quality of life for patients with Gaucher disease.
Eliglustat capsules, marketed as Cerdelga®, are approved for treating Gaucher disease type 1 in both the US and EU. The FDA and EMA reviewed comprehensive regulatory dossiers, including clinical trial data, manufacturing standards, and safety profiles, to ensure high-quality standards. These dossiers support regulatory approval and facilitate market access. Cerdelga® capsules are available in an 84 mg strength, offering an effective oral therapy option. For detailed information on the regulatory process, dossier submissions, and market approvals, visit PharmaTradz, your source for pharmaceutical regulatory insights and updates.